Skip to content

Assessing the Impact of COVID-19 Patients Long Distance Transfers Between Intensive Care Units

TRANSCOV Cohort. An Epidemiological Study Assessing the Impact of Critically Ill COVID-19 Patients Long Distance Transfers Between Intensive Care Units

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04930120
Acronym
TRANSCOV
Enrollment
3060
Registered
2021-06-18
Start date
2021-03-01
Completion date
2022-12-31
Last updated
2021-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

The TRANSCOV cohort is a multicentre observational retrospective study aiming at assessing the health impact of extra regional transfers of critically ill COVID-19 patients.

Detailed description

In spring 2020 four regions of France faced a surge of severe Coronavirus (COVID) patients which threatened to overflow local intensive care units (ICU) capacities. As an emergency response, between 03/13/2020 and 04/10/2020, an estimated 661 patients were transferred from overcrowded ICUs to other French regions and neighbouring countries. The study aims at assessing the impact of these inter-ICU transfers on the short and medium term physical and psychological outcomes in this population of severe COVID 19 patients. All transferred patients between ICUs outside the origin region are invited to take part. For each transfer, up to four control patients will be selected among those admitted in the same ICU during the same period (+/-4 days of transfer date). Clinical data will be extracted from medical records and will include hemodynamic and respiratory parameters, as well as clinical severity scores before, during and after transfer. Data linkage with medico-administrative data will enrich the clinical database and allow follow-up up to one year after initial admission.

Interventions

OTHERInter ICU long distance patient transfer

Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.

Sponsors

Ecole des Hautes Etudes en Santé Publique
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* COVID-19 patients diagnosed biologically or by imaging * Admission in ICU between 03/13/2020 and 04/10/2020

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Survival1 yearStatus alive or dead

Countries

France

Contacts

Primary ContactOlivier Grimaud, Ph.D., M.D
olivier.grimaud@ehesp.fr02 99 02 28 34
Backup ContactChristophe Fermanian, Ph.D.
christophe.fermanian@ehesp.fr02 99 02 24 69

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026